Yield10 Bioscience
YTEN
P/S ratio for Yield10 Bioscience (YTEN)
P/S ratio as of May 2024 (TTM): 15.7
According to Yield10 Bioscience's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 15.7141. At the end of 2023 the company had a P/S ratio of 23.9.
P/S ratio history for Yield10 Bioscience from 2006 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 23.9 | -1.88% |
| 2022 | 24.3 | -37.76% |
| 2021 | 39.1 | 62.19% |
| 2020 | 24.1 | 203.59% |
| 2019 | 7.94 | -46.92% |
| 2018 | 15.0 | -6.99% |
| 2017 | 16.1 | 88% |
| 2016 | 8.56 | -55.02% |
| 2015 | 19.0 | -4.25% |
| 2014 | 19.9 | 135.71% |
| 2013 | 8.43 | 602.65% |
| 2012 | 1.20 | -98.9% |
| 2011 | 109 | -85.09% |
| 2010 | 731 | 255.36% |
| 2009 | 206 | 9.46% |
| 2008 | 188 | -31.48% |
| 2007 | 274 | 242.43% |
| 2006 | 80.0 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Nymox Pharmaceutical NYMX | N/A | N/A | Bahamas |
 NRC Health
NRC | 5.07 | -67.72% | 🇺🇸 USA |